Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?.

Abdominal radiology (New York)

Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J.
PMID: 34773467
Abdom Radiol (NY). 2021 Nov 13; doi: 10.1007/s00261-021-03339-7. Epub 2021 Nov 13.

PURPOSE: To evaluate whether the Liver Imaging Reporting and Data System (LI-RADS) v2018 LR-5 criteria can be modified to increase sensitivity without reducing specificity for diagnosing 10-19 mm hepatocellular carcinoma (HCC) on gadoxetic acid-enhanced magnetic resonance imaging (MRI).METHODS: A...

Cite
Xie S, Zhang Y, Chen J, et al. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?. Abdom Radiol (NY). 2021;doi: 10.1007/s00261-021-03339-7.
Xie, S., Zhang, Y., Chen, J., Jiang, T., Liu, W., Rong, D., Sun, L., Zhang, L., He, B., & Wang, J. (2021). Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?. Abdominal radiology (New York), . https://doi.org/10.1007/s00261-021-03339-7
Xie, Sidong, et al. "Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?." Abdominal radiology (New York) vol. (2021). doi: https://doi.org/10.1007/s00261-021-03339-7
Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?. Abdom Radiol (NY). 2021 Nov 13; doi: 10.1007/s00261-021-03339-7. Epub 2021 Nov 13. PMID: 34773467.
Copy Download .nbib Format: NLM
Magnetic resonance elastography of the prostate in patients with lower urinary tract symptoms: feasibility of the modified driver at high multi-frequencies.

Abdominal radiology (New York)

Deng Y, Yi Z, Zhang T, Hu B, Zhang L, Rajlawot K, Kuang S, He B, Arani A, Chen J, Yin M, Rossman P, Glaser KJ, Venkatesh SK, Ehman RL, Wang J.
PMID: 34635941
Abdom Radiol (NY). 2021 Oct 11; doi: 10.1007/s00261-021-03302-6. Epub 2021 Oct 11.

PURPOSE: To demonstrate the feasibility and diagnostic value of high-frequency magnetic resonance elastography (MRE) for evaluation of prostatic disease in patients with lower urinary tract symptoms (LUTS).METHODS: 41 patients who underwent preoperative prostate MRI and MRE with a modified...

Cite
Deng Y, Yi Z, Zhang T, et al. Magnetic resonance elastography of the prostate in patients with lower urinary tract symptoms: feasibility of the modified driver at high multi-frequencies. Abdom Radiol (NY). 2021;doi: 10.1007/s00261-021-03302-6.
Deng, Y., Yi, Z., Zhang, T., Hu, B., Zhang, L., Rajlawot, K., Kuang, S., He, B., Arani, A., Chen, J., Yin, M., Rossman, P., Glaser, K. J., Venkatesh, S. K., Ehman, R. L., & Wang, J. (2021). Magnetic resonance elastography of the prostate in patients with lower urinary tract symptoms: feasibility of the modified driver at high multi-frequencies. Abdominal radiology (New York), . https://doi.org/10.1007/s00261-021-03302-6
Deng, Ying, et al. "Magnetic resonance elastography of the prostate in patients with lower urinary tract symptoms: feasibility of the modified driver at high multi-frequencies." Abdominal radiology (New York) vol. (2021). doi: https://doi.org/10.1007/s00261-021-03302-6
Deng Y, Yi Z, Zhang T, Hu B, Zhang L, Rajlawot K, Kuang S, He B, Arani A, Chen J, Yin M, Rossman P, Glaser KJ, Venkatesh SK, Ehman RL, Wang J. Magnetic resonance elastography of the prostate in patients with lower urinary tract symptoms: feasibility of the modified driver at high multi-frequencies. Abdom Radiol (NY). 2021 Oct 11; doi: 10.1007/s00261-021-03302-6. Epub 2021 Oct 11. PMID: 34635941.
Copy Download .nbib Format: NLM
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII

Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J.
PMID: 33993366
Cancer Immunol Immunother. 2022 Jan;71(1):25-38. doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16.

BACKGROUND: Tumor-infiltrating CD8 cells and expression of programmed cell death ligand 1 (PD-L1) are immune checkpoint markers in patients with hepatocellular carcinoma (HCC). We aimed to determine the ability of preoperative gadoxetic acid-enhanced magnetic resonance imaging (MRI) findings to...

Cite
Sun L, Mu L, Zhou J, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2021;71(1):25-38doi: 10.1007/s00262-021-02957-w.
Sun, L., Mu, L., Zhou, J., Tang, W., Zhang, L., Xie, S., Chen, J., & Wang, J. (2022). Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer immunology, immunotherapy : CII, 71(1), 25-38. https://doi.org/10.1007/s00262-021-02957-w
Sun, Lin, et al. "Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma." Cancer immunology, immunotherapy : CII vol. 71,1 (2022): 25-38. doi: https://doi.org/10.1007/s00262-021-02957-w
Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2022 Jan;71(1):25-38. doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16. PMID: 33993366.
Copy Download .nbib Format: NLM
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII

Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J.
PMID: 33993366
Cancer Immunol Immunother. 2021 May 16; doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16.

BACKGROUND: Tumor-infiltrating CD8 cells and expression of programmed cell death ligand 1 (PD-L1) are immune checkpoint markers in patients with hepatocellular carcinoma (HCC). We aimed to determine the ability of preoperative gadoxetic acid-enhanced magnetic resonance imaging (MRI) findings to...

Cite
Sun L, Mu L, Zhou J, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2021;doi: 10.1007/s00262-021-02957-w.
Sun, L., Mu, L., Zhou, J., Tang, W., Zhang, L., Xie, S., Chen, J., & Wang, J. (2021). Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer immunology, immunotherapy : CII, . https://doi.org/10.1007/s00262-021-02957-w
Sun, Lin, et al. "Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma." Cancer immunology, immunotherapy : CII vol. (2021). doi: https://doi.org/10.1007/s00262-021-02957-w
Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2021 May 16; doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16. PMID: 33993366.
Copy Download .nbib Format: NLM
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII

Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J.
PMID: 33993366
Cancer Immunol Immunother. 2022 Jan;71(1):25-38. doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16.

BACKGROUND: Tumor-infiltrating CD8 cells and expression of programmed cell death ligand 1 (PD-L1) are immune checkpoint markers in patients with hepatocellular carcinoma (HCC). We aimed to determine the ability of preoperative gadoxetic acid-enhanced magnetic resonance imaging (MRI) findings to...

Cite
Sun L, Mu L, Zhou J, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2021;71(1):25-38doi: 10.1007/s00262-021-02957-w.
Sun, L., Mu, L., Zhou, J., Tang, W., Zhang, L., Xie, S., Chen, J., & Wang, J. (2022). Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer immunology, immunotherapy : CII, 71(1), 25-38. https://doi.org/10.1007/s00262-021-02957-w
Sun, Lin, et al. "Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma." Cancer immunology, immunotherapy : CII vol. 71,1 (2022): 25-38. doi: https://doi.org/10.1007/s00262-021-02957-w
Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2022 Jan;71(1):25-38. doi: 10.1007/s00262-021-02957-w. Epub 2021 May 16. PMID: 33993366.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries